GlaxoSmithKline plc (GSK) Holdings Reduced by Keybank National Association OH
Keybank National Association OH decreased its holdings in shares of GlaxoSmithKline plc (NYSE:GSK) by 9.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 84,042 shares of the pharmaceutical company’s stock after selling 8,304 shares during the period. Keybank National Association OH’s holdings in GlaxoSmithKline were worth $2,981,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC raised its position in GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,351 shares during the last quarter. Field & Main Bank bought a new position in GlaxoSmithKline during the 4th quarter valued at approximately $132,000. First Dallas Securities Inc. bought a new position in GlaxoSmithKline during the 4th quarter valued at approximately $142,000. Advisory Services Network LLC raised its position in GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after purchasing an additional 788 shares during the last quarter. Finally, Waldron LP bought a new position in GlaxoSmithKline during the 3rd quarter valued at approximately $203,000. 9.52% of the stock is owned by institutional investors and hedge funds.
A number of research firms have commented on GSK. Cowen reaffirmed a “hold” rating and set a $40.00 price target on shares of GlaxoSmithKline in a research report on Thursday. Kepler Capital Markets raised GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research report on Friday, February 9th. TheStreet lowered GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, February 5th. Finally, ValuEngine lowered GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $38.97.
GlaxoSmithKline (NYSE:GSK) last announced its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a return on equity of 130.63% and a net margin of 4.97%. The firm had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. research analysts expect that GlaxoSmithKline plc will post 2.85 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be given a $0.633 dividend. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 annualized dividend and a dividend yield of 6.72%. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio is currently 258.23%.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.